Sei Investments Co. Makes New Investment in Celldex Therapeutics, Inc. $CLDX

Sei Investments Co. bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the first quarter, Holdings Channel reports. The firm bought 38,152 shares of the biopharmaceutical company’s stock, valued at approximately $1,210,000.

A number of other institutional investors also recently modified their holdings of CLDX. Wilmington Savings Fund Society FSB purchased a new position in shares of Celldex Therapeutics during the 3rd quarter valued at $42,000. Russell Investments Group Ltd. raised its holdings in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Celldex Therapeutics during the third quarter worth $63,000. Kestra Advisory Services LLC acquired a new stake in Celldex Therapeutics during the fourth quarter valued at $98,000. Finally, Advisory Services Network LLC acquired a new stake in Celldex Therapeutics during the third quarter valued at $139,000.

Celldex Therapeutics Stock Up 3.2%

NASDAQ:CLDX opened at $44.33 on Wednesday. Celldex Therapeutics, Inc. has a 12 month low of $20.19 and a 12 month high of $44.60. The firm has a market cap of $3.48 billion, a price-to-earnings ratio of -10.19 and a beta of 0.87. The company’s 50 day moving average is $35.76 and its 200-day moving average is $31.83.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. Research analysts predict that Celldex Therapeutics, Inc. will post -4.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Canaccord Genuity Group lowered their target price on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Cantor Fitzgerald reduced their price target on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $42.00 price target on shares of Celldex Therapeutics in a research note on Monday, June 15th. Finally, Barclays increased their price objective on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $55.46.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.